Sarepta Therapeutics (NASDAQ:SRPT) had its price target cut by research analysts at Cantor Fitzgerald from $217.00 to $128.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 55.55% from the stock’s current price.
A number of other research analysts have also weighed in on SRPT. Credit Suisse Group reduced their price target on Sarepta Therapeutics from $162.00 to $156.00 and set a “neutral” rating on the stock in a research note on Monday, December 14th. Piper Sandler increased their price target on Sarepta Therapeutics from $200.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday, January 4th. Smith Barney Citigroup increased their price target on Sarepta Therapeutics from $190.00 to $215.00 in a research note on Monday, December 14th. Morgan Stanley lowered Sarepta Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $182.00 to $95.00 in a research note on Friday. Finally, Citigroup increased their price target on Sarepta Therapeutics from $177.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $164.83.
SRPT stock opened at $82.29 on Friday. Sarepta Therapeutics has a 1 year low of $78.06 and a 1 year high of $181.83. The company has a debt-to-equity ratio of 0.67, a quick ratio of 6.42 and a current ratio of 6.93. The stock’s 50 day moving average price is $159.66 and its 200 day moving average price is $151.22. The firm has a market cap of $6.49 billion, a P/E ratio of -11.72 and a beta of 1.82.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($2.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.89) by ($0.61). Sarepta Therapeutics had a negative net margin of 117.80% and a negative return on equity of 53.02%. The company had revenue of $143.92 million during the quarter, compared to analysts’ expectations of $133.69 million. During the same period in the previous year, the company posted ($1.14) EPS. Sarepta Therapeutics’s quarterly revenue was up 45.3% compared to the same quarter last year. On average, research analysts predict that Sarepta Therapeutics will post -7.57 earnings per share for the current year.
In related news, insider Joseph Bratica sold 1,115 shares of the stock in a transaction on Friday, December 11th. The stock was sold at an average price of $165.00, for a total value of $183,975.00. Following the completion of the sale, the insider now directly owns 9,255 shares in the company, valued at approximately $1,527,075. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in SRPT. Amundi Pioneer Asset Management Inc. increased its holdings in Sarepta Therapeutics by 32.8% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company’s stock valued at $18,428,000 after purchasing an additional 38,194 shares in the last quarter. American International Group Inc. grew its stake in shares of Sarepta Therapeutics by 26.9% during the second quarter. American International Group Inc. now owns 2,036 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 431 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in shares of Sarepta Therapeutics by 299.3% during the second quarter. Ensign Peak Advisors Inc now owns 6,613 shares of the biotechnology company’s stock valued at $1,060,000 after acquiring an additional 4,957 shares in the last quarter. First Republic Investment Management Inc. acquired a new stake in shares of Sarepta Therapeutics during the second quarter valued at about $234,000. Finally, Baird Financial Group Inc. grew its stake in shares of Sarepta Therapeutics by 9.9% during the second quarter. Baird Financial Group Inc. now owns 5,598 shares of the biotechnology company’s stock valued at $722,000 after acquiring an additional 503 shares in the last quarter. Hedge funds and other institutional investors own 92.70% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Featured Story: Technical Analysis of Stocks, How Can It Help
